Skip to content
Login Register

#ADCs

2 public questions tagged with this topic.

Immunological Applications

Antibody–drug conjugates (ADCs) combine:

Antibody-drug conjugates integrate precision of biologics with potency of small molecules to overcome poor therapeutic window of conventional chemotherapy that diffuses into all tissues causing systemic toxicity. Monoclonal antibody component provides tumor-selective homing through high affinity binding Kd 10^-9 to 10^-11 M to antigens preferentially expressed on malignant cells ten to hundred fold over normal tissues, such as HER2, CD30, CD22, and internalization via receptor mediated endocytosis clathrin dependent trafficking to early endosome then late endosome fusing with lysosome pH 4.5 containing cathepsins B and L. Chemical linker connecting payload determines release kinetics: cleavable valine-citrulline dipeptide sensitive to lysosomal cathepsin B with PABC self-immolative spacer, acid-labile hydrazone stable at neutral pH 7.4 but hydrolyzes at pH below 6.0, disulfide sensitive to cytosolic glutathione 1000 fold higher than plasma. Non-cleavable thioether linker SMCC requires complete proteolytic degradation of antibody backbone to release lysine-MCC-drug metabolite still active. This mechanistic insight supports diagnostic and therapeutic applications while reinforcing core immunological and cell biology principles taught in advanced curricula.

Ref: Beck et al Nat Rev Drug Discov 2017 16:315 ADC linker payload MMAE DM1; Trail Cancer Immunol Res auristatin maytansine.

View Details
Immunological Applications

Antibody–drug conjugates (ADCs) combine:

Antibody-drug conjugates engineered targeted chemotherapy combining precision monoclonal antibody recognition lethal payload potency too toxic systemic administration alone narrow therapeutic index causing severe myelosuppression neuropathy. Monoclonal antibody component typically humanized IgG1 kappa 150 kDa produced CHO cells reduced fucosylation enhancing Fc gamma receptor affinity binds tumor-associated antigen nanomolar affinity CD30 120 kDa TNFRSF8 Hodgkin Reed-Sternberg anaplastic large cell HER2 185 kDa tyrosine kinase amplified breast adenocarcinoma CD33 67 kDa sialic acid-binding Ig-like lectin AML blasts undergoing rapid receptor-mediated internalization clathrin-mediated endocytosis forming early endosome pH 6.0 trafficking lysosome pH 4.5 acidic hydrolases cathepsin B L cleaving linker releasing drug. Cytotoxic cargo microtubule inhibitors MMAE 718 Da synthetic dolastatin 10 analog binding vinca site near beta-tubulin interface preventing polymerization causing mitotic arrest G2/M maytansinoid DM1 DM4 binding near vinblastine site suppressing dynamic instability DNA minor groove alkylator calicheamicin gamma1 double-strand breaks Bergman cyclization diradical abstracting deoxyribose hydrogens. Linker chemistry governs stability plasma cleavable valine-citrulline dipeptide substrate cathepsin B para-aminobenzyl carbamate self-immolative spacer disulfide reduced glutathione enriched tumor noncleavable SMCC thioether requiring complete antibody degradation generating lysine adduct retaining potency. Average drug-antibody ratio 3.5-4 balanced maintaining solubility pharmacokinetics delivering sufficient payload conjugation

Ref: FDA Guidance Antibody Drug Conjugates 2020 Principles; Nature Reviews Drug Discovery ADC Technology Evolution 2022; Trail et al Antibody Drug Conjugates Design Development.

View Details